Related Experiment Videos
Antithrombotic actions of statins
A Szczeklik1, A Undas, J Musial
1Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland. mmszczek@cyf-kr.edu.pl
Insights
Simvastatin treatment reduces thrombin generation and blood clotting in patients with hypercholesterolemia and coronary heart disease. This effect appears independent of cholesterol-lowering, possibly due to reduced isoprenoid production.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Hematology
Background:
- Aspirin inhibits thrombin generation via platelet macromolecule acetylation, an effect diminished in hypercholesterolemia.
- Hypercholesterolemia and coronary heart disease are associated with altered hemostasis and increased thrombin generation.
Purpose of the Study:
- To investigate the effect of simvastatin treatment on thrombin generation and blood clotting in patients with hypercholesterolemia and coronary heart disease.
- To explore the potential mechanisms underlying simvastatin's influence on coagulation, independent of its lipid-lowering effects.
Main Methods:
- Assessed tissue-factor initiated coagulation in blood samples from patients with advanced coronary artery disease and hypercholesterolemia before and after three months of simvastatin treatment.
- Measured thrombin generation at basal conditions in venous blood and after microvascular injury.
- Analyzed rates of prothrombin activation, Factor Va generation and inactivation, fibrinogen cleavage, and Factor XIII activation.
Main Results:
- Simvastatin treatment significantly reduced thrombin generation in both basal and activated hemostasis conditions.
- Blood clotting was depressed following simvastatin therapy, evidenced by reduced prothrombin activation, Factor Va generation, fibrinogen cleavage, and Factor XIII activation.
- An increased rate of Factor Va inactivation was observed post-simvastatin treatment.
- These coagulation changes occurred in patients with both marked hypercholesterolemia and borderline-high cholesterol levels associated with coronary heart disease.
Conclusions:
- Simvastatin exerts an inhibitory effect on thrombin generation and the clotting cascade, independent of its lipid-lowering action.
- The observed effects suggest that simvastatin's influence on coagulation may be mediated by the depression of isoprenoid production.
- These findings highlight a potential non-lipid-lowering mechanism of statins impacting hemostasis, relevant for cardiovascular disease management.
Abstract:
Aspirin depresses thrombin generation, probably through a mechanism independent of the cyclooxygenase inhibition, but rather related to acetylation of the platelet membrane macromolecules. This action of aspirin is blunted in hypercholesterolemia. In men with marked hypercholesterolemia, lowering serum cholesterol by a three-month simvastatin treatment is accompanied by a reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury. Similar results are obtained in patients with coronary heart disease and borderline - high cholesterol levels. We assessed tissue-factor initiated coagulation in blood samples collected every 30-seconds from bleeding time wounds in patients with advanced coronary artery disease and total cholesterol levels of 224 mg/dL. Three-month simvastatin treatment depressed blood clotting, leading to reduced rates of prothrombin activation, FVa generation, fibrinogen cleavage, FXIII activation, and an increased rate of FVa inactivation. Such a concerted influence of statins on the clotting cascade seems to be independent of their lipid-lowering action and may be the result of depressed isoprenoid production.